Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Reducing Dscam1 diversity decreases adult lifespan in an exon-specific manner, Related to Fig 3. by Haiyang Dong (4783608)

MeV <i>M</i> mRNA quantification in cells treated with an inhibitor of RNA polymerase III. by Pierre Khalfi (7868252)

Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

“…</p><p>Conclusion:CLEC16A variants conferred a decreased risk to AR in the Chinese population.…”

Table1_CLEC16A variants conferred a decreased risk to allergic rhinitis in the Chinese population.DOCX by Yongliang Niu (14245295)

“…</p><p>Conclusion:CLEC16A variants conferred a decreased risk to AR in the Chinese population.…”

Fig 7 - by Jianbo Jia (717814)

Estimates of BMI category coefficients to predict the mean increase or decrease in postoperative OKS. by Jonathan Thomas Evans (9322437)

Retinoic acid alleviates decreases of phospho-Akt and phospho-Bad expression caused by MCAO damage. by Ju-Bin Kang (16021324)

“…Phospho-PDK1, phospho-Akt, phospho-Bad expressions were decreased in vehicle + MCAO animals, retinoic acid treatment alleviated these decreases. …”

Comparison of forward resistance. by Jianbo Jia (717814)

“…Finally, by making corresponding test blocks, it was found that the peak value of forward resistance when the 10.5°test block crossed the steps of 1mm, 2mm and 3mm height decreased by 19.8%, 25.0% and 13.9% respectively, and the mean value decreased by 30.8%, 27.2% and 24.1% respectively, which was close to the simulation results, and verified the accuracy of the finite element analysis results.…”